Objective: This study aims to investigate the impact of indacaterol/glycopyrrolate on pulmonary function and St. George's Respiratory Questionnaire (SGRQ) scores in patients with stable chronic obstructive pulmonary disease (COPD).
Methods: A prospective randomized controlled trial (RCT) was conducted. A total of 100 stable COPD patients admitted to our hospital between September 2020 and October 2022 were selected as study participants. They divided into a conventional group (n=50) and a combined compound preparation (CCP) group (n=50) using a random number table. The conventional group received oral carbocisteine tablets, while the combined compound preparation group received indacaterol/glycopyrrolate inhalation powder spray in addition to the conventional treatment. Clinical efficacy, pulmonary function indices, serum inflammatory factors, psychological resilience, and quality of life were compared between the two groups.
Results: The CCP group exhibited a significantly higher total effective rate (92.00%) compared to the conventional group (76.00%) (P < .05). Post-treatment, both groups showed increased values in forced expiratory volume in the first second (FEV1), forced vital capacity (FVC), FEV1/FVC ratio, and FEV1% with a more substantial improvement in the CCP group (P < .05). Additionally, the CCP group demonstrated decreased post-treatment levels of serum inflammatory factors (TNF-α, IL-6, CRP, and PCT), elevated scores on the Connor Davidson Resilience Scale (CD-RISC), and reduced SGRQ scores compared to the conventional group (P < .05).
Conclusions: In treatment of stable COPD patients, the combination of indacaterol/glycopyrrolate with carbocisteine tablets enhances pulmonary function, alleviates airway inflammatory reactions, improves clinical efficacy, enhances psychological resilience, and elevates the quality of life compared to carbocisteine tablets alone. These findings underscore the potential therapeutic benefits of the combined compound preparation in managing stable COPD.